Marksans Pharma Ltd has announced its quarterly earnings conference call to discuss the unaudited financial results for the third quarter of fiscal year 2026. The company informed stock exchanges about this scheduled investor interaction through a regulatory filing under Regulation 30 of SEBI listing requirements.

Conference Call Schedule

The earnings conference call has been scheduled for the following details:

Management Participation

The company's senior leadership will represent Marksans Pharma during the investor call:

• Mark Saldanha - Founder, Chairman and Managing Director
• Jitendra Sharma - Chief Financial Officer
• Nitin Agarwal - Analyst, DAM Capital Advisors Ltd (Call Leader)

Access Information

Investors and analysts can participate in the conference call through multiple dial-in options. The company has provided universal access numbers (+91 22 6280 1384, +91 22 7115 8285) accessible from all networks and countries. International participants can use dedicated toll-free numbers for Hong Kong, Singapore, UK, and USA.

Documentation and Records

Following the conference call, Marksans Pharma will make comprehensive documentation available to stakeholders. The company has confirmed that the presentation materials, complete audio recording of the call, and detailed transcript will be hosted on the company's official website at marksanspharma.com under the earnings call transcripts section.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Harshavardhan Panigrahi signed the regulatory communication sent to both BSE Limited and National Stock Exchange of India Limited on January 22, 2026.

Marksans Pharma Limited has announced a significant development in its UK operations. The company's wholly-owned subsidiary, Relonchem Limited, has received marketing authorization for Cetirizine Dihydrochloride 1 mg/ml Oral Solution from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Product Details

Strategic Implications

This regulatory approval marks an important milestone for Marksans Pharma, as it:

• Expands the company's product portfolio in the UK pharmaceutical market
• Strengthens its presence in the antihistamine medication segment
• Potentially opens up new revenue streams in the UK healthcare sector

Cetirizine, an antihistamine medication, is commonly used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing. The approval of the oral solution formulation may provide an alternative option for patients who have difficulty swallowing tablets or prefer liquid medications.

Company Background

Marksans Pharma Limited, headquartered in Mumbai, India, is a global pharmaceutical company engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company's manufacturing facilities, located in India, USA, and UK, are approved by several leading regulatory agencies, including the US FDA, UK MHRA, and Australian TGA.

The company's product portfolio spans major therapeutic segments, including cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, anti-allergies, upper respiratory, oncology, and antibiotics.

This latest approval aligns with Marksans Pharma's strategy of expanding its presence in key global markets and diversifying its product offerings. As the pharmaceutical landscape continues to evolve, such regulatory approvals play a crucial role in a company's growth and market positioning.